| Steven L Kastl, DO | |
|
1900 Pine St, Abilene, TX 79601-2432 | |
| (325) 670-2151 | |
| Not Available |
| Full Name | Steven L Kastl |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine - Emergency Medical Services |
| Location | 1900 Pine St, Abilene, Texas |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508855461 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207PE0004X | Emergency Medicine - Emergency Medical Services | G0877 (Texas) | Primary |
| Entity Name | Midland Emergency Management Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801889993 PECOS PAC ID: 5092773614 Enrollment ID: O20041229000772 |
News Archive
Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy. If scientists could put a "homing beacon" in tumors, they could attract these medicines and reduce side effects caused by the drugs acting on healthy cells.
According to new report from the Nurses' Health Study (NHS), regular, long-term aspirin use can significantly reduce the risk of colorectal cancer.
Innate Therapeutics today announced funding support from Fast Forward, LLC, a not-for-profit organization established by the U.S. National Multiple Sclerosis Society and EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany. The award of funds will help support the conduct of a Phase 2A clinical trial in patients with progressive forms of MS using MIS416, a naturally occurring agent derived from bacteria.
› Verified 2 days ago
| Entity Name | Pinnacle Emergency Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982664801 PECOS PAC ID: 4880671882 Enrollment ID: O20050120000060 |
News Archive
Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy. If scientists could put a "homing beacon" in tumors, they could attract these medicines and reduce side effects caused by the drugs acting on healthy cells.
According to new report from the Nurses' Health Study (NHS), regular, long-term aspirin use can significantly reduce the risk of colorectal cancer.
Innate Therapeutics today announced funding support from Fast Forward, LLC, a not-for-profit organization established by the U.S. National Multiple Sclerosis Society and EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany. The award of funds will help support the conduct of a Phase 2A clinical trial in patients with progressive forms of MS using MIS416, a naturally occurring agent derived from bacteria.
› Verified 2 days ago
| Entity Name | Guadalupe Emergency Medicine Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114425220 PECOS PAC ID: 0941561781 Enrollment ID: O20180219001747 |
News Archive
Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy. If scientists could put a "homing beacon" in tumors, they could attract these medicines and reduce side effects caused by the drugs acting on healthy cells.
According to new report from the Nurses' Health Study (NHS), regular, long-term aspirin use can significantly reduce the risk of colorectal cancer.
Innate Therapeutics today announced funding support from Fast Forward, LLC, a not-for-profit organization established by the U.S. National Multiple Sclerosis Society and EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany. The award of funds will help support the conduct of a Phase 2A clinical trial in patients with progressive forms of MS using MIS416, a naturally occurring agent derived from bacteria.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven L Kastl, DO Po Box 5210, Norman, OK 73070-5210 Ph: (866) 321-8433 | Steven L Kastl, DO 1900 Pine St, Abilene, TX 79601-2432 Ph: (325) 670-2151 |
News Archive
Psyadon Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study ecopipam in patients with Lesch-Nyhan Disease (LND). The first center at which the drug will be evaluated is Emory University under the direction of Dr. Hyder A. Jinnah, MD, PhD. The study is designed to evaluate the safety and tolerability of different doses of ecopipam in adults (group 1), adolescents (group 2) and children (group 3) with LND.
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy. If scientists could put a "homing beacon" in tumors, they could attract these medicines and reduce side effects caused by the drugs acting on healthy cells.
According to new report from the Nurses' Health Study (NHS), regular, long-term aspirin use can significantly reduce the risk of colorectal cancer.
Innate Therapeutics today announced funding support from Fast Forward, LLC, a not-for-profit organization established by the U.S. National Multiple Sclerosis Society and EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany. The award of funds will help support the conduct of a Phase 2A clinical trial in patients with progressive forms of MS using MIS416, a naturally occurring agent derived from bacteria.
› Verified 2 days ago
Dr. Gerald P. Gibson, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 4438 S Clack St, Abilene, TX 79606 Phone: 325-704-4470 Fax: 325-704-4485 | |
Dr. Adam Edward Majkowski, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1900 Pine St, Trauma Center, Abilene, TX 79601 Phone: 325-670-2151 | |
Dr. Anthony S. Rossettie, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1900 Pine St, Abilene, TX 79601 Phone: 607-368-2625 | |
Dr. Colin Bumann, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 8433 Saddle Creek Rd, Abilene, TX 79602 Phone: 580-585-5545 | |
Dr. Janeen James, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 1634 State Highway 351, Abilene, TX 79601 Phone: 325-676-1101 Fax: 325-676-1104 | |
Stephen J Jackson, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 4716 S 14th St, Abilene, TX 79605 Phone: 325-232-8668 Fax: 325-701-9970 | |
Dr. Robert Eugene Phillips, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3478 Catclaw Dr # 263, Abilene, TX 79606 Phone: 866-363-0761 Fax: 866-689-0766 |